Inclisiran in lipid management: A Literature overview and future perspectives

Scicchitano, Pietro; Milo, Michele; Mallamaci, Rosanna; Palo, Micaela De; Caldarola, Pasquale; Massari, Francesco; Gabrielli, Domenico; Colivicchi, Furio; Ciccone, Marco Matteo

doi:10.1016/j.biopha.2021.112227

Cited by 36 publications

(26 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, new antilipemic drugs, such as proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, are becoming more and more readily available. Though they are currently not widely prescribed in primary care, they may modify the impact of health check frequency on lipid control in the near future ( 22 , 23 ). In addition, we noticed that this significant impact exists only in total cholesterol but not in low-density lipoprotein cholesterol or triglyceride.…”

Section: Discussionmentioning

confidence: 99%

The Association Between the Frequency of Annual Health Checks Participation and the Control of Cardiovascular Risk Factors

Tang

Zhang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundGeneral health checks can help in controlling cardiovascular risk factors. However, few studies have investigated whether regular participation in annual health checks could further improve the control of cardiovascular risk factors compared with intermittent participation. Therefore, our study aimed to explore the association between the frequency of annual health check participation and the control of cardiovascular risk factors.MethodsResidents aged ≥ 65 years or having chronic diseases (hypertension or diabetes) from 37 communities of Guangzhou, Guangdong, who participated in the Basic Public Health Service project between January 2015 and December 2019, were enrolled and divided into 3 groups (“Sometimes,” “Usually,” and “Always”) according to their frequencies of annual health check participation. Multivariable linear regression models were performed to assess the association between the frequency of annual health check participation and the control of cardiovascular risk factors. A subgroup analysis stratified by gender was also conducted.ResultsIn total, 9,102 participants were finally included. Significant differences were identified between groups in systolic blood pressure (SBP), diastolic blood pressure (DBP), weight, fasting glucose, total cholesterol, high-density lipoprotein cholesterol, and serum creatinine. After fully adjusting for confounding factors, residents who always participated in the annual health check tended to have lower SBP (β = −4.36, 95% CI: −5.46; −3.26, p < 0.001), fasting glucose (β = −0.27, 95% CI: −0.38; −0.15, p < 0.001), and total cholesterol (β = −0.19, 95% CI: −0.26; −0.13, p < 0.001), compared with those who attended sometimes. Furthermore, gender did not alter these associations.ConclusionA higher frequency of annual health check participation was associated with lower SBP, fasting glucose, and total cholesterol.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association Between the Frequency of Annual Health Checks Participation and the Control of Cardiovascular Risk Factors

Tang

Zhang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Another method to target PCSK9 is with inclisiran, a small interfering RNA (siRNA) therapy that inhibits translation of messenger-RNA (mRNA) [ 48 , 49 ]. Inclisiran has two strands, each 21–23 nucleotides in length, that interacts with the RNA-induced silencing complex (RISC), which then binds with PCSK9 mRNA, preventing translation of the PCSK9 protein [ 48 , 49 ]. During drug development, several chemical modifications occur to increase the compound’s potency and duration of action [ 48 , 49 ].…”

Section: Proprotein Convertase Subtilisin-kexin Type 9 (Pcsk9) Inhibi...mentioning

confidence: 99%

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk

Rikhi

Shapiro

2022

JCM

View full text Add to dashboard Cite

Multiple lines of evidence demonstrate that low-density lipoprotein-cholesterol causes atherosclerotic cardiovascular disease. Thus, targeting and lowering low-density lipoprotein-cholesterol is the principal strategy to reduce cardiovascular disease risk in primary and secondary prevention. Statin therapy is the foundation of lipid-lowering treatment, but adherence rates are low, and many individuals do not attain target low-density lipoprotein-cholesterol values. Additionally, most statin-treated patients are still at considerable atherosclerotic cardiovascular disease risk, emphasizing the need for more aggressive low-density lipoprotein-cholesterol-lowering therapies. The purpose of this review is to discuss new and emerging approaches to further lower low-density lipoprotein-cholesterol, including inhibition of ATP-citrate lyase, proprotein convertase subtilisin-kexin type 9, angiopoietin-related protein 3, and cholesteryl ester transfer protein.

show abstract

“…Inclisiran is an injectable small interfering (or silencing) ribonucleic acid agent that impairs hepatic PCSK9 synthesis and is administered every 6 months (twice a year). [171] Oral PCSK9 formulations are in development. Hypertriglyceridemia (≥ 150 mg/dL) generally increases the risk for ASCVD (i.e., high triglycerides are part of the diagnostic criteria for the metabolic syndrome) [31] and especially increases ASCVD risk if the elevated triglyceride (TG) levels represent an increase in atherogenic triglyceride-rich lipoproteins (e.g., very-low-density lipoproteins, intermediate density lipoproteins, remnant lipoproteins) [172] and their remnants.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%